Amgen Inc. (NASDAQ:AMGN) is currently regarded as one of the most undervalued stocks in the S&P 500 worth considering for purchase. William Blair analyst Matt Phipps recently affirmed a Buy rating on Amgen, although he did not set a specific price target.
Despite setbacks in the FORTITUDE-101 trial, where Bemarituzumab showed limited survival benefits in treating gastric cancer, Phipps remains hopeful about the next phase. He is particularly optimistic about FORTITUDE-102, which integrates Bemarituzumab with chemotherapy and Opdivo, anticipating it to be crucial for regulatory approvals and market impact.
Phipps commended Amgen’s management for their strategic adaptability in response to trial outcomes. He believes that their ability to modify timelines and strategies based on results is a strong indicator of potential long-term growth.
Amgen Inc. focuses on the discovery and development of medications for serious illnesses. Their main goal is to address diseases that have significant unmet medical needs.
The broader portfolio of Amgen remains robust, which supports the analyst’s positive outlook. This robustness is seen as a pillar for the company’s ongoing and future endeavors.
While Amgen shows promise, there are opinions that certain AI stocks might present less risk and more upside potential. Some analysts suggest these AI stocks could benefit greatly from policies established during the Trump administration, specifically tariffs and the trend towards onshoring.
For those interested in exploring further investment opportunities, there are reports highlighting AI stocks with potential for significant short-term gains. These reports identify 30 stocks expected to double in three years and uncover 11 lesser-known AI stocks currently poised for purchase.
It is important to note that the views expressed here are based on the analyses provided by financial experts and market analysts. These insights are aimed at guiding potential investors in making informed decisions.
Disclosure statements clarify that the information provided does not involve any conflict of interest or personal stakes by the authors. They serve to ensure transparency and maintain the integrity of the advice provided.
This article was originally crafted and published by Insider Monkey, a platform known for its financial insights and stock market analysis.
